title: Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma.
abstract: There is little information on pulmonary metastasectomy of urinary tract transitional cell carcinoma (TCC). In this study, we examined the long-term outcome and the factors associated with long-term survival after pulmonary metastasectomy of urinary tract TCC based on a 20-year single center experience. Between 1984 and 2005, 18 patients (12 men, six women) underwent pulmonary metastasectomy of the urinary tract TCC in our hospital. The clinicopathological and surgical data of these patients obtained from the medical records were analyzed in this retrospective study. The time interval between lung resection and death, or latest follow-up ranged from two to 200 months (median 52). Survival analysis was conducted by the Kaplan-Meier method and log-rank test. The cumulative three- and five-year survival rates were 59.8% and 46.5%, respectively. The number of resected metastatic tumors (solitary vs. multiple) was associated with long-term survival (P<0.05). The five-year survival rate of patients with solitary metastasis was 85.7% while that of patients with multiple metastases was 20.0%. Pulmonary metastasectomy of urinary tract TCC is associated with a favorable outcome, and solitary metastasis is associated with long-term survival. Aggressive management of solitary pulmonary metastasis from a urinary tract TCC is feasible in selected patients.
authors.affiliation: Department of Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan. rkanzaki@tj8.so-net.ne.jp
authors.forename: Ryu
authors.initials: R
authors.lastname: Kanzaki
authors.forename: Masahiko
authors.initials: M
authors.lastname: Higashiyama
authors.forename: Ayako
authors.initials: A
authors.lastname: Fujiwara
authors.forename: Toshiteru
authors.initials: T
authors.lastname: Tokunaga
authors.forename: Jun
authors.initials: J
authors.lastname: Maeda
authors.forename: Jiro
authors.initials: J
authors.lastname: Okami
authors.forename: Kazuo
authors.initials: K
authors.lastname: Nishimura
authors.forename: Ken
authors.initials: K
authors.lastname: Kodama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011013:Pneumonectomy; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000473:pathology*